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Abstract
Purpose—This Phase I dose-escalation study investigated the maximum tolerated dose (MTD), 
dose-limiting toxicities (DLTs), safety, pharmacokinetics (PK), pharmacodynamics (PD) and 
preliminary clinical activity of CH5132799.
Patients and Methods—Patients with metastatic solid tumors were eligible for the study. 
CH5132799 was administered orally once daily (QD) or twice daily (BID) in 28-day cycles.
Results—Thirty-eight patients with solid tumors received CH5132799 at 2-96 mg QD or 48-72 
mg BID. The MTD was 48 mg on the BID schedule but was not reached on the QD schedule. 
DLTs were grade 3 elevated liver function tests (LFT), grade 3 fatigue, grade 3 encephalopathy, 
grade 3 diarrhea and grade 3 diarrhea with grade 3 stomatitis; all DLTs were reversible. Most 
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drug-related adverse events were grade 1/2. Diarrhea (34%) and nausea (32%) were the most 
common events. Mean Cmax and AUC0-24 in steady state at MTD were 175 ng/ml and 1,550 
ng·hr/ml respectively, consistent with efficacious exposure based on preclinical modelling. 
Reduction in SUVmax with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) 
was observed in five of seven patients at MTD. A patient with PIK3CA-mutated clear cell 
carcinoma of the ovary achieved a partial response by GCIG CA125 criteria and further, a heavily 
pre-treated patient with triple negative breast cancer had marked improvement in her cutaneous 
skin lesions lasting 6 cycles.
Conclusion—CH5132799 is well tolerated at the MTD dose 48 mg BID. At this dose the drug 
had a favorable PK and PD profile and preliminary evidence of clinical activity.
Keywords
Phase I; Class I PI3K inhibitor; CH5132799; dose-escalation; advanced/metastatic solid tumors
Introduction
The intracellular phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of 
rapamycin (mTOR) pathway regulates cellular functions such as cell survival, proliferation, 
growth, apoptosis, protein synthesis and glucose metabolism (1-6). Of the three classes of 
PI3K (I to III), class IA is implicated most in cancer (5). Class IA PI3K heterodimers 
comprise a p85-regulatory and a p110-catalytic subunit with several isoforms (5). Mutation 
or amplification of PIK3CA, the gene encoding the catalytic subunit of PI3K (p110α), 
promotes oncogenic activation of the PI3K pathway and occurs frequently in human cancers 
such as ovarian cancer and breast cancer (1, 6-12). Phosphatase and tensin homolog 
(PTEN), a key negative regulator of AKT, can be inactivated via mutations, down-
regulation, or loss of protein expression, and is associated with tumorigenesis in prostate, 
gastric and other cancers (1, 13-19). Moreover, it is likely that PI3K pathway activation is 
associated with resistance to both chemotherapy (20-22) and targeted agents (23-26). 
Selective inhibition of the PI3K/AKT/mTOR pathway in cancer represents a promising 
therapeutic approach and has been the focus of significant research efforts including the 
clinical development of novel agents targeting this pathway (1, 19, 27-37).
CH5132799 (Chugai Pharmaceutical Co Ltd, Tokyo, Japan) is an oral PI3K inhibitor with 
specific and potent activity against class I PI3Ks, especially demonstrated in wild-type and 
mutant PI3Kα isoforms, and PI3Kγ at nanomolar concentrations(38). CH5132799 has no 
inhibitory activity against class III PI3K, or mammalian target of rapamycin (mTOR) (38). 
In vitro experiments demonstrated a strong antiproliferative effect of CH5132799 on human 
cancer cell lines with alterations in the PI3K pathway (38, 39). In vivo, CH5132799 
demonstrated significant antitumor activity in human tumor xenograft models with PIK3CA 
mutations, with good correlation between CH5132799 exposure and inhibition of PI3K 
signalling (39).
The primary objective of this first-in-human, Phase I, dose escalation study was to determine 
the MTD of CH5132799 using a continuous oral schedule in patients with advanced solid 
tumors. Secondary objectives included the characterisation of CH5132799 PK, and the PD 
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profile of PI3K inhibition in tumor and in surrogate tissues such as peripheral blood 
samples, and by [18F] fluorodeoxyglucose positron emission tomography (FDG-PET).
Patients and Methods
Study population
Patients had been diagnosed with advanced solid tumors that were not amenable or were 
refractory to standard therapy. Patients were aged ≥18 years with an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0-2 and adequate bone marrow, renal, 
hepatic and cardiac function were enrolled (see supplementary data for detailed inclusion 
and exclusion criteria) and a life expectancy of ≥12 weeks.
This study was approved by an independent ethics committee (The Royal Marsden Research 
Ethics Committee, London, United Kingdom) and conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice (GCP). Written informed consent was 
obtained from all patients before carrying out any study-related procedures.
Study design and CH5132799 dose escalation
This open-label dose-escalation study was conducted at four centers. Prior to the first 
treatment cycle, CH5132799 was administered as a single oral dose followed by a 5–7 day 
washout (run-in period). A classical “3+3” design was used for dose-escalation with QD to 
the early patient cohorts, and then BID to others, continuously in 4-week cycles. Dose 
escalation was determined by the nature and grade/severity of toxicities.
The primary objective was to determine the MTD of CH5132799 based on DLTs observed 
during the run-in period and first 4-week cycle. The MTD was defined as the highest dose 
level at which no more than one of six patients experienced a DLT. A starting dose of 2 mg 
was chosen based on the highest non-severe toxic dose in a non-rodent species and the 
severely toxic dose (10% lethal dose) in rat, which means 7.8-fold and 30-fold safety 
margins were applied to the two metabolically/kinetically relevant animal species, 
respectively (40).
Assessments
Medical history and demographic data were collected at baseline. Physical examination, 
monitoring of vital signs and other safety assessments were performed throughout the study. 
All toxicities were documented using Common Terminology Criteria for Adverse Events 
(CTCAE) V4.03 (41). DLTs were defined as grade ≥3 non-hematologic toxicity despite 
adequate treatment, grade 4 neutropenia lasting ≥7 days, febrile neutropenia, grade 4 
thrombocytopenia lasting ≥7 days or requiring a platelet transfusion.
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors 
(RECIST; version 1.1) with imaging at baseline and every two cycles (42).
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Pharmacokinetics and Pharmacodynamics
Plasma PK samples were collected on Cycle 0, Day 1, followed by Cycle 1, Days 1, 8, 15 
and 22. Plasma concentrations of CH5132799 were measured by a validated LC/MS/MS 
assay method (Chugai Pharmaceutical Co. Ltd., Kamakura, Japan, data on file) and PK 
parameters calculated by non-compartmental analysis with first-order oral absorption 
(WinNonlin Ver 5.3 and Phoenix WinNonlin Ver.6.1 (Pharsight Corporation, NC, USA). 
The CH5132799-related inhibition of AKT phosphorylation (pAKT) was studied in platelet-
rich plasma (PRP). Blood for PRP samples was collected at 0 (pre-dose), 1, 2, 6, 24, 48 and 
72 hrs post-dose on Day 1 of the run-in period (Cycle 0, Day 1) and at 0 (pre-dose) on Cycle 
1, Day 15. Blood samples were collected into BD Vacutainer sodium citrate coagulation 
tubes and centrifuged at 200 × g at 4°C for 15 minutes. The isolated PRP layer was 
incubated with PhosSTOP (Roche) to stabilize the phosphorylation signals and then lysed 
using Cell Lysis Buffer (Cell Signaling Technology) containing phenylmethane sulfonyl 
fluoride (Sigma-Aldrich) and then snap-frozen on dry ice. PD analysis with PRP was 
performed by The Institute of Cancer Research. All PRP samples were analysed for the 
levels of phosphorylated and total forms of PD biomarker AKT by a Meso Scale 
Discovery® electrochemiluminescent assay (ECLA). The assay was modified into a GCP-
compliant quantitative assay for AKT by inclusion of a standard curve of recombinant active 
AKT protein on every plate. The quality, accuracy and precision of the assays were 
monitored using quality control (QC) samples created by spiking three known quantities of 
recombinant AKT into 10% human plasma.
Biopsies were performed at screening and at Cycle 1, Day 15. Flash frozen tumor biopsies 
were homogenized using a micro tissue grinder in Cell Lysis Buffer (w/v) containing 
PhosSTOP. The tumor lysates were centrifuged to remove debris and the protein 
concentration measured using the BCA assay (Pierce). Tumor biopsy samples were analysed 
for the levels of phosphorylated and total forms of PD biomarker AKT by a quantitative ICR 
modified GCP compliant Meso Scale Discovery® electrochemiluminescent assay (ECLA). 
[18F] Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging was 
performed within 28 days prior to the first dosing of CH5132799, Cycle 1, Day 8, and Cycle 
3, Day 1. Lesions with the highest degree of FDG uptake were selected for quantitative 
analysis and a circular/spherical region of interest drawn. A SUVmax was measured for each 
selected lesion and the delta change in SUVmax was calculated. Tumor biopsies were taken 
after FDG-PET scanning to avoid interference of biopsy on FDG uptake.
Detection of mutations
PIK3CA/KRAS/BRAF mutations were studied with the OncoCarta panel v1.0 and detected 
by mass ARRAY System.
Statistical analyses
Descriptive statistics were used for the analysis of PK, PD, safety and tumor response data.
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Results
Thirty-eight patients received at least one dose of CH5132799 (Table 1), of whom 23 
received CH5132799 QD (2-96 mg/day). The decision to dose BID was made as there had 
been no DLTs and no significant increase in drug concentrations at doses above 56 mg QD 
along with PD measures i.e. recovery of p-AKT after 12 hours. Subsequently 15 further 
patients then received CH5132799 BID (96–144 mg/day). Overall, patients received a 
median of 2 cycles (range 0–6), with a median duration of 52 days of treatment (range 1–
164 days). Archival tumor samples were available in 30 patients. PIK3CA mutations were 
found in 10% (3/30) of samples studied (Table 1).
Dose-limiting toxicities
DLTs were observed in five of 38 evaluable patients who received CH5132799 BID and 
completed the first cycle (Table 2A). Of seven patients at 48 mg BID, one patient with 
hepatocellular carcinoma experienced grade 3 elevated transaminases. Although the patient 
had liver metastases with elevated LFTs (grade 2) at baseline, a causal link to CH5132799 
could not be excluded because clear evidence of disease progression in liver metastasis was 
not observed. At the next dose level, two of three patients receiving 72 mg BID had DLTs. 
One had grade 3 fatigue that was resolved following cessation of CH5132799 and she 
restarted CH5132799 with reduced dose when fatigue had been resolved and she did not 
experience the event later on, whilst the other developed grade 3 posterior reversible 
encephalopathy syndrome (PRES) that was presented with seizures. The diagnosis was 
made on characteristic MRI findings and the symptoms resolved on cessation of 
CH5132799 as well as instigation of supportive care without restarting CH5132799. Two of 
five patients receiving the intermediate dose of 56 mg BID had grade 3 diarrhea, the other 
grade 3 diarrhea with grade 3 stomatitis, which resolved following cessation of CH5132799 
and instigation of supportive treatment, in both cases study treatment was then restarted at a 
reduced dose without further DLTs. Therefore, the MTD and recommended phase 2 dose 
(RP2D) of CH5132799 administered orally was established at 48 mg BID.
Safety
The most common AEs were: diarrhea, nausea, stomatitis, fatigue, and rash which occurred 
in 68%, 32%, 32%, 29% and 24% of patients, respectively (Table 2B). Diarrhea was 
predominantly grade 1 or 2, with no grade 4 diarrhea reported. Four patients experienced 
grade 3 diarrhea (96 mg QD, n=2; 56 mg BID, n=2). One patient experienced grade 3 
nausea (96 mg QD). No grade ≥3 gastrointestinal AEs occurred in the cohort who received 
CH5132799 at the R2PD (48 mg BID). Hyperglycemia was predicted due to the mechanism 
of action of CH5132799. Five patients experienced Grade ≥3 hyperglycemia in the BID 
dosing schedule suggesting a dose-dependent effect (48 mg BID, n=1; 56 mg BID, n=2; 72 
mg BID; n=2 including one Grade 4). No episodes of diabetic ketoacidosis occurred and 
hyperglycemia was controlled with oral metformin as required. No drug-related deaths were 
reported.
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Pharmacokinetics
Following oral administration of a single dose of CH5132799, plasma concentrations peaked 
with a Tmax at 2.60 hours and t1/2 of 10.2 hours at the MTD (Figure 1A). Dose 
proportionality of AUC was shown in the dose range of 2 to 56 mg (Figure 2B). Steady state 
was reached by Cycle 1, Day 8 at the latest with little subsequent accumulation; there was 
no further increase in AUC at higher doses. At the MTD of 48 mg BID, mean Cmax and 
AUClast were 172 ng/mL and 1,270 ng·hr/mL after a single dose, respectively. Mean Cmax 
and AUC0-24h were 175 ng/mL and 1,550ng·hr/mL at steady state, respectively (Table 3).
Pharmacodynamics
Significant inhibition of PI3K signalling was observed in PRP, with reduction of AKT 
phosphorylation at doses of 32 mg and above (Figure 2A). The temporal relationship 
between reduction in phosphorylation of AKT and dosing administration with CH5132799 
suggested target engagement for less than 24 hours (Figure 2B). This observation 
contributed to the decision to increase dosing frequency to BID.
Pre- and post-treatment tumor biopsies were optional and the minimum number to be 
conducted during the study was not based on statistical assumptions. Tumor biopsy samples 
were collected before and after CH5132799 from three patients (one patient each on 56 mg 
QD, 96 mg QD and 56 mg BID). There was a more than 50% reduction in normalized p-
AKT levels in two of the three patients (Figure 2C).
A decrease in FDG avidity between baseline and Cycle 1, Day 8 was observed in 74% of 
patients (17/23) who underwent serial PET imaging (Figure 2D). It was interesting that five 
of seven patients at the RP2D who had pre-and post- (Cycle1, Day 8) treatment PET scans 
showed a reduction in maximum standardised uptake value (SUVmax); two had a reduction 
in SUVmax of 55% and 44%.
There was no correlation between the PD changes in the limited number of biopsies, PET 
responses or PRP inhibition.
Efficacy
There were no RECIST partial or complete responses but one patient with PIK3CA H1047R-
mutated clear cell ovarian cancer had a GCIG CA125 response having been treated at 48 mg 
BID and remained on study for 6 cycles (Figure 3A). A second patient with heavily pre-
treated triple negative breast cancer bearing no PIK3CA or AKT mutations who was treated 
at the 72 mg BID dose level had marked symptomatic and objective improvement in her 
cutaneous skin lesions and remained on treatment for 6 cycles (Figure 3B). Disease 
stabilisation was seen in eight patients up to week 16 (approximately 4 cycles), including 
two patients with PIK3CA mutation.
Discussion
We report the first-in-human study of an oral PI3K class I inhibitor CH5132799. No DLTs 
occurred at the QD schedule, but the BID schedule was selected based on the duration of 
target inhibition observed in platelet-rich plasma and the lack of dose dependent incremental 
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elevation in concentrations of drug above 56 mg QD. The BID schedule of CH5132799 was 
well tolerated and showed evidence of clinical and PD activity with a RP2D of 48 mg BID.
The most frequently observed toxicities were gastrointestinal, including diarrhea, nausea and 
stomatitis. These have been described previously in studies of PI3K, AKT and m-TOR 
inhibitors (28, 30-38). Reversible grade 3 LFT elevation was observed in one of seven 
patients treated at the MTD of 48 mg BID. This patient with hepatocellular carcinoma had 
liver metastases and had previously undergone hepatic resection, therefore the event was 
possibly caused by disease progression and/or overload of a liver with insufficient metabolic 
capability. No other cases of drug-related LFT abnormalities were noted although they have 
been described in trials of other PI3K inhibitors (30-32, 34, 43). Of note, we observed one 
case of PRES at a dose above the MTD. This has not been reported previously in the trials of 
other drugs in this class, nevertheless, it raised the possibility that CH5132799 crosses the 
blood-brain barrier, which may be of future relevance in the treatment of patients with 
intracerebral malignancies. Mood alterations have been described as adverse events in with 
other PI3 kinase inhibitors (30, 43), however was not seen in this trial. Although skin-related 
toxicities have been frequently observed in the trials of other PI3K inhibitors (28-30, 32, 33, 
35-37, 43-45), CH5132799 was associated with only mild to moderate skin toxicities at a 
lower frequency. On-target toxicity such as hyperglycemia was observed with CH5132799 
as with other PI3K, AKT and m-TOR inhibitors (28-30, 35-37, 44, 45) although did not 
result in ketoacidosis was well-controlled by metformin. The favorable toxicity profile of 
CH5132799 may make it suitable to combine with other targeted agents such as epidermal 
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) or MAPK/ERK kinase (MEK) 
inhibitors.
The PK data show it was possible to attain CH5132799 concentrations in patients that had 
been efficacious in xenograft models(39). The AUC increased proportionally with dose from 
2-56 mg. The PD data indicated target modulation using phosphorylation of AKT at Sr473 
as a proof of mechanism biomarker. Levels of p-AKT were reduced in PRP consistently at 
dose levels 8 – 96 mg. The maximal inhibition approximately 50% compared to baseline and 
this was achieved at dose levels of 32 mg. p-AKT levels in PRP frequently recovered by 24 
hrs following treatment. The duration of PD biomarker changes in normal tissue and the fact 
that there were no significant further reduction in p-AKT levels after the 32 mg cohort, 
along with the fact that the AUC of CH5132799 did not rise significantly above 56 mg, led 
us to explore a twice-weekly schedule, despite not reaching an conventional MTD at 96 mg 
on the once-daily dosing cohorts. At the recommended phase II dose of 48 mg BID levels of 
p-AKT were reduced in PRP and in a limited number of post-treatment tumor biopsies. 
There was a reduction in levels of p-AKT (Ser473) in 2/3 tumor at the higher dose levels but 
there was considerable variation in reduction between patients (Figure 2c). The degree of p-
AKT reduction in the tumor from patients were less than what was seen in xenograft models 
(39), however this could reflect different platforms to assess AKT phosphorylation and other 
factors such as intra-tumoral heterogeneity.
Further evidence of tumor target modulation was observed with FDG-PET scans with all 
patients at recommended dose. All five patients scanned at the RP2D having a reduction in 
SUVmax and two of them achieved a PET response by PERCIST criteria (46). Although the 
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number of patients is too small to draw definitive conclusions, these PD data are highly 
encouraging. There was no correlation between the PD changes in the limited number of 
biopsies and PET responses or PRP inhibition. The FDG PET was done pre-treatment and 
on day 8 of treatment while tumor biopsies were performed pre-treatment and day 15 of 
treatment while the detailed p-AKT studies in PRP were done on day 1 of treatment. The 
small number of biopsies and the disparities in the days when tests were conducted could 
have led to the lack of correlation between p-AKT levels in tumor, PRP and changes in 
SUVmax on PET.
The eight study participants (21%) showing a best response of stable disease by RECIST 
included two participants who with clear clinical responses. In reports of other PI3K, AKT 
and mTOR inhibitors as single agent in patients with solid tumors, disease stabilization was 
observed, but only a few cases of radiological response have been reported (28-32, 34-36, 
44). Therefore, there was clinical evidence as well as PD activity for CH5132799. These 
results indicated that CH5132799 was comparable to other PI3K, AKT and m-TOR 
inhibitors in terms of single agent activity.
Three patients were found to have PIK3CA mutations. Although there were no objective 
radiologic responses, it was interesting that one of these patients (with clear cell ovarian 
cancer) had a GCIG-defined partial response in her CA125 tumor marker. Another patient 
with triple negative breast cancer had a visible response in cutaneous metastases. This 
patient with breast cancer did not have any PIK3CA mutation, although triple negative 
breast cancer was known frequently to diseases associated with other perturbations in PI3K 
pathway (47). Pre-clinical models suggest that PIK3CA mutations predict for sensitivity to 
PI3K inhibitors as either single agents (48, 49) or in combination (50). This was also seen 
with preclinical studies of CH5132799(39). However, the clinical correlation of between 
PIK3CA mutations and PI3K inhibitors to this has not been fully realised (51) in the clinic 
and it is possible that other activating mutations (52) or intra-tumoral heterogeneity (53) 
may play a role.
We conclude that CH5132799 at RP2D of 48 mg BID is well tolerated and attains drug 
concentrations which show evidence of achieving target engagement in both normal tissues 
and tumor. CH5132799 has clinical as well as PD activity which was one with evidence of 
proof-of-mechanism from a clinical response in one patient with PIK3CA mutant ovarian 
cancer patient. The favorable toxicity profile and activity observed with single-agent 
CH5132799 suggests it is suitable for combination with other targeted therapies, and for 
exploration in subsets of patients with cancers harboring pre-defined mutations.
Supplementary Material
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Translational Relevance
CH5132799 is an oral pan-PI3 kinase inhibitor designed to target both alpha and beta 
isoforms of PI3K, which are frequently deregulated in cancer due to activating mutations 
in the oncogene PIK3CA or loss of function of the tumor suppressor gene, PTEN. The 
dosing schedule was to be determined by toxicity, PK and PD parameters and started 
with a QD schedule followed if necessary by a BID schedule. The trial started with 
CH5132799 administered orally once a day (QD) but a formal MTD was not reached at 
96 mg however as there were no significant increments in AUC above a dose of 56 mg 
QD and p-AKT showed recovery at 24 hrs. Therefore, the dosing schedule was modified 
to include twice a day dosing (BID). A dose of 48 mg BID was declared the 
recommended phase II dose, at which dose a patient with PIK3CA mutant clear cell 
ovarian cancer responded.
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Figure 1. Pharmacokinetic parameters of CH5132799
A) Plasma concentration of CH5132799 following a single administration across the dose 
range of 2 mg – 96 mg. B) The correlation of the AUC (area under the curve) of CH5132799 
and dose. The horizontal lines indicate effective AUC calculated to cause TGI (tumor grown 
inhibition) of 50% and 90% of the KPL4 and HCT116 xenograft models.
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Figure 2. Pharmacodynamic parameters of CH5132799
A) Mean percentage change of phosphorylated AKT normalized to total AKT compared to 
pre-treatment control values, 2 hrs following a single dose of CH5132799. B) The temporal 
course of plasma concentration of CH5132799 and the percentage change of p-AKT 
normalized to total AKT compared to pre-treatment control values following a single dose 
of the recommended phase II dose of CH5132799 (48 mg). C) Percentage change of p-AKT 
normalized to total AKT in tumor biopsies when compared to pre-treatment samples. D) 
SUVmax changes on FDG-PET scans in patients who had evaluable pre- and post-treatment 
FDG-PET scans.
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Figure 3. Clinical efficacy of CH5132799
A) FDG-PET-CT showing reduction in uptake of tracer in pelvic masses and a reduction of 
CA125 following treatment with CH5132799. The patient had a clear cell ovarian cancer 
which harbored a PIK3CA mutation. B) Representative skin lesions, before and after 
treatment with CH5132799, of a patient with triple-negative breast cancer.
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Table 1
Patient demographics and clinical characteristics
Characteristic Total patients (N=38)
Sex
Male 10 (26%)
Female 28 (74%)
Age, years
Median 58.5
Range 41-76
Race
Asian 3 (8%)
Black 3 (8%)
White 32 (84%)
Baseline ECOG performance status
0 12 (32%)
1 25 (66%)
2 1 (3%)
Prior anti-cancer therapies, median (range) 3 (1–8)
Primary tumor site and mutational status
Breast 10 (26%)
 No mutation 8
 Unknown mutational status 2
Ovarian 6 (16%)
  KRAS G12D 1
  PIK3CA H1047R 1
  No mutation 3
  Unknown mutational status 1
Oesophageal and oesophageal-gastric adenocarcinoma 5 (13%)
  KRAS G12D 1
  EGFR S768I 1
  No mutation 3
Duodenal and large intestine 4 (11%)
  KRAS G12A 1
  KRAS G12D and PIK3CA E545K 1
 No mutation 2
Gastric* 2 (5%)
Lung* 2 (5%)
Endometrial* 1 (3%)
Vagina* 1 (3%)
Myonetrium* 1 (3%)
Vulva* 1 (3%)
Bladder* 1 (3%)
Pancreas* 1 (3%)
Prostate* 1 (3%)
Unknown primary origin 1 (3%)
  PIK3CA E545K 1
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Table 2 A
Dose limiting toxicities seen on the study
Cohor Dose N DLT 1
7b 48 mg BID 7 grade 3 elevated LFT at Cycle 1 Day 8
8 72 mg BID 3 grade 3 cerebral encephalopathy at Cycle 1, Day 14
grade 3 Fatigue at Cycle 1 Day8
9 56 mg BID 5 grade 3 Diarrhea
grade 3 Diarrhea and stomatitis (<75% of the total scheduled dose)
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Table 3
Summary of pharmacokinetics of CH5132799 in patients following oral administration
Regimen
Single dose Repeat dose
***Accumulation ratio
*AUClast (ng·hr/mL) Cmax (ng/mL) t1/2 (hr) **AUC0-24h (ng·hr/mL) Cmax (ng/mL)
2mg (QD) 53.0(3) 10.0(3) 7.52(3) 48.8(3) 9.92(3) 0.912(3)
4 mg (QD) 112(3) 17.2(3) 8.30(3) 167(3) 22.5(3) 1.54(3)
8 mg (QD) 133(3) 41.1(3) 23.7(3) 159(2) 46.3(2) 1.22(2)
16 mg (QD) 883(1) 113(1) 13.7(1) 621(2) 100(3) 0.972(1)
32 mg (QD) 859(4) 165(4) 12.2(4) 1740(2) 345(3) 1.57(2)
56 mg (QD) 969(3) 163(3) 14.5(3) 748(3) 184(3) 1.07(3)
96 mg (QD) 1650(4) 206(4) 23.2(3) 691(3) 103(3) 0.640(3)
48 mg (BID) 1270(4) 172(5) 10.2(4) 1550(5)** 175(5) 1.10(2)
56 mg (BID) 3030(5) 428(5) 16.3(5) 5940(2)** 331(3) 1.72(2)
72 mg (BID) 2480(3) 265(3) 18.3(3) 5580(1)** 631(1) 2.25(1)
Footnote to Table 2: Mean value and number (noted in parenthesis) are represented for each pharmacokinetic parameter.
*AUClast in single dose represented AUC0-72h.
**AUC0-24h in BID regimen of repeat dose were calculated based on the data from 0 to 12 hours (AUC0-12h).
***Accumulation ratio represents AUC0-24h/0-12h in repeat dose / AUC0-24h/0-12h in single dose. AUC: area under the plasma concentration 
time curve, Cmax: maximum concentration measured, t1/2: elimination half-life
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